0001145443-13-000228.txt : 20130208 0001145443-13-000228.hdr.sgml : 20130208 20130208160230 ACCESSION NUMBER: 0001145443-13-000228 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130206 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20130208 DATE AS OF CHANGE: 20130208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOHEART, INC. CENTRAL INDEX KEY: 0001388319 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 650945967 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33718 FILM NUMBER: 13586788 BUSINESS ADDRESS: STREET 1: 13794 NW 4TH STREET STREET 2: SUITE 212 CITY: SUNRISE STATE: FL ZIP: 33325 BUSINESS PHONE: 954-835-1500 MAIL ADDRESS: STREET 1: 13794 NW 4TH STREET STREET 2: SUITE 212 CITY: SUNRISE STATE: FL ZIP: 33325 8-K 1 d30199.htm 8-K



U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________

FORM 8-K

____________________


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) February 6, 2013


____________________


Commission File No. 001-33718

____________________


Bioheart, Inc.

(Name of small business issuer as specified in its charter)


           Florida                                                                                                                       65-0945967

 State of Incorporation                                                                                          IRS Employer Identification No.


13794 NW 4th Street, Suite 212, Sunrise, Florida 33325

(Address of principal executive offices)


 (954) 835-1500

(Issuer’s telephone number)

 


Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):


o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




In this Current Report on Form 8-K, “Company,” “our company,” “us,” and “our” refer to Bioheart, Inc., unless the context requires otherwise.

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 6, 2016, Howard J. Leonhardt resigned as Chief Technology Officer, Chairman of the Scientific Advisory Board, and as a member of the Board of Directors to pursue other business matters. In tendering his resignation, Mr. Leonhardt did not express any disagreement with the Company on any matter relating to its operations, policies or practices.   





SIGNATURES


Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Registrant

Date: February 8, 2013


 

Bioheart, Inc.

 By: /s/ Mike Tomas

 

 

Mike Tomas

 

 

Chief Executive Officer